Instructions and precautions for use of Dacomitinib/Dozerun

Dacomitinib/Dacomitinib (Dacomitinib) is an oral tablet, and the dosage needs to be adjusted according to the patient's physical condition, type of genetic mutation, and tolerance. In general, it is recommended as first-line treatment for patients with non-small cell lung cancer carrying EGFR sensitive mutations. It should be taken orally at a fixed dose every day and continued until disease progression or intolerable toxicity occurs. During the medication process, patients should strictly follow the doctor's instructions and should not stop medication, increase or decrease the dose, or change the medication time at will to ensure efficacy and safety.

During the course of taking the medicine, patients may experience side effects such as rash, diarrhea, stomatitis, nail changes, and mild to moderate liver function abnormalities, and require regular follow-up and monitoring of blood, liver and kidney functions. For patients who experience serious adverse reactions, they should contact their doctor promptly and adjust the dose or temporarily discontinue the drug if necessary. During long-term medication, patients also need to pay attention to lifestyle adjustments, such as avoiding sun exposure, keeping skin clean and eating a balanced diet, to help reduce side effects.

In addition, dacomitinib needs to be vigilant for drug interactions when used in combination. Some CYP2D6 and CYP3A4 metabolism pathway drugs may affect the plasma concentration of dacomitinib, thereby changing the efficacy or increasing the risk of toxicity. Therefore, patients should provide complete medication information to their doctors when taking other medications at the same time so that reasonable adjustments can be made. Special groups such as pregnant women, lactating women and patients with severely impaired liver and kidney function should use it with caution under the guidance of a doctor.

Dacomitinib is a prescription drug, and patients must purchase it through regular hospitals or pharmacies to ensure that the source of the drug is legal and reliable. In short, rational drug use, regular monitoring and doctor-advised management are the keys to ensuring the therapeutic effect of dacomitinib and reducing the risk of adverse reactions. For patients with EGFR-positive NSCLC, Dozerun provides a sustainable, precise and quality-of-life targeted treatment option.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro